Impact of Healthcare Insurance System Reforms and Policies to Contain Medical Costs

「Sales of Forxiga tablets, a treatment for diabetes, chronic heart failure and chronic kidney disease, were ¥88.2 billion, down ¥1.4 billion, or 1.5%, from the previous consolidated fiscal year due to the entry of generics in December 2025.」

「Sales of the oncology drug Opdivo intravenous infusion were ¥120.3 billion, down ¥25.2 billion, or 17.3%, from the previous consolidated fiscal year due in part to the drug-price cut.」

「Sales of the oncology drug Opdivo intravenous infusion were ¥62.6 billion, down ¥12.4 billion, or 16.5%, year on year due to the impact of the drug-price cut.」

「If selling prices decline due to the impact of healthcare system reforms, such as cuts to official drug prices and measures to promote generic use in Japan, as well as various healthcare cost-containment measures overseas, and the decline cannot be offset by higher sales volumes or other factors, the Group's performance and financial position may be affected if revenue declines.」

「Long-listed products were affected by drug-price revisions and other factors. Sales of Opalmon tablets were ¥2.3 billion, down 5.9% year on year, and Onon capsules were ¥1.2 billion, down 35.3%.」

「Long-listed products were affected by drug-price revisions and other factors. Sales of Opalmon tablets were ¥1.1 billion, down 6.5% year on year, and Onon capsules were ¥0.7 billion, down 36.3%.」

「Long-listed products were affected by measures to promote generic use and other factors. Sales of Opalmon tablets were ¥4.7 billion, down 13.4% from the previous consolidated fiscal year, and Rivastach patches were ¥2.9 billion, down 56.6%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥3.7 billion, down 14.2% year on year, and Rivastach patches were ¥2.3 billion, down 61.0%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥2.4 billion, down 16.8% year on year, and Rivastach patches were ¥1.6 billion, down 61.7%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥1.2 billion, down 17.5% year on year, and Rivastach patches, a treatment for Alzheimer-type dementia, were ¥0.8 billion, down 60.7%.」

「Long-listed products were affected by measures to promote generic use. Sales of Rivastach patches, a treatment for Alzheimer-type dementia, were ¥6.6 billion, down 22.5% from the previous consolidated fiscal year; Opalmon tablets were ¥5.5 billion, down 34.5%; and Ricalbon tablets were ¥2.9 billion, down 39.9%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥2.9 billion, down 35.4% year on year; Ricalbon tablets were ¥1.5 billion, down 41.3%; and Emend capsules, a treatment for nausea and vomiting associated with oncology drug administration, were ¥1.5 billion, down 67.8%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥1.5 billion, down 36.8% year on year; Ricalbon tablets were ¥0.8 billion, down 42.5%; and Emend capsules, a treatment for nausea and vomiting associated with oncology drug administration, were ¥0.8 billion, down 64.1%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥8.3 billion, down 19.5% from the previous consolidated fiscal year, and Ricalbon tablets were ¥4.7 billion, down 35.4%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥6.7 billion, down 19.0% from the first nine months of the previous fiscal year, and Ricalbon tablets were ¥3.9 billion, down 36.7%.」

「Long-listed products were affected by measures to promote generic use. Sales of Opalmon tablets were ¥4.5 billion, down 19.2% from the first six months of the previous fiscal year, and Ricalbon tablets were ¥2.6 billion, down 41.1%.」

「Although use of the oncology drug Opdivo intravenous infusion expanded for renal cell carcinoma, sales were ¥22.3 billion, down ¥0.5 billion, or 2.0%, from the first quarter of the previous consolidated fiscal year, due to the impact of the drug-price review in November last year and intensifying competition from competing products.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥10.4 billion, down 27.9% from the previous consolidated fiscal year, and Ricalbon tablets were ¥7.3 billion, down 32.8%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥8.3 billion, down 28.7% from the first nine months of the previous fiscal year, and Ricalbon tablets were ¥6.1 billion, down 28.3%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥5.5 billion, down 26.8% from the first six months of the previous fiscal year, and Ricalbon tablets, a treatment for osteoporosis, were ¥4.4 billion, down 19.0%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥2.9 billion, down 23.1% from the first quarter of the previous fiscal year; Onon capsules were ¥1.1 billion, down 14.6%; and Onon dry syrup was ¥0.7 billion, down 14.3%.」

「Although use of the oncology drug Opdivo intravenous infusion has expanded for renal cell carcinoma, head and neck cancer, gastric cancer, for which an additional indication was approved in September 2017, and other cancers, sales were ¥90.1 billion, down ¥13.8 billion, or 13.3%, from the previous consolidated fiscal year, due in part to the 50% drug-price cut implemented in February 2017.」

「Although use of the oncology drug Opdivo intravenous infusion has expanded for cancer types including renal cell carcinoma and head and neck cancer, for which additional indications were approved in the previous fiscal year, and gastric cancer, for which an additional indication was approved in September 2017, sales were ¥69.0 billion, down ¥13.6 billion, or 16.5%, year on year, due in part to the 50% drug-price cut implemented in February 2017.」

「Although use of the oncology drug Opdivo intravenous infusion has expanded for cancer types including renal cell carcinoma and head and neck cancer, for which additional indications were approved last year, sales were ¥40.6 billion, down ¥12.7 billion, or 23.8%, from the first six months of the previous fiscal year, due in part to the 50% drug-price cut implemented in February 2017.」

「Although use of the oncology drug Opdivo intravenous infusion has expanded for cancer types including renal cell carcinoma and head and neck cancer, for which additional indications were approved last year, sales were ¥19.8 billion, down ¥5.4 billion, or 21.4%, from the first quarter of the previous fiscal year, due in part to the 50% drug-price cut implemented in February 2017.」

「Long-listed products were affected by competing products and measures to promote generic use. Sales of Opalmon tablets were ¥17.0 billion, down 25.0% from the previous consolidated fiscal year; Onon capsules were ¥6.8 billion, down 24.2%; and Onon dry syrup was ¥4.1 billion, down 26.7%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥13.4 billion, down 26.3% from the first nine months of the previous fiscal year; Onon capsules were ¥4.8 billion, down 26.2%; and Foypan tablets were ¥3.0 billion, down 27.5%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets were ¥8.8 billion, down 25.9% from the first six months of the previous fiscal year; Onon capsules were ¥3.0 billion, down 25.6%; and Foypan tablets were ¥2.0 billion, down 27.0%.」

「Long-listed products were affected by drug-price revisions and measures to promote generic use. Sales of Opalmon tablets, a treatment for peripheral circulatory disorders, were ¥4.7 billion, down 24.8% from the first quarter of the previous fiscal year; Onon capsules, a treatment for bronchial asthma and allergic rhinitis, were ¥1.7 billion, down 23.3%; and Foypan tablets, a treatment for chronic pancreatitis and postoperative reflux esophagitis, were ¥1.1 billion, down 25.6%.」

「Although we expect the uncertain environment to continue, including as various health insurance system reforms are implemented, the performance and financial position of the Group may be materially affected by developments in these reforms.」